公开(公告)号：EP2816114A3

公开(公告)日：2015-02-25

申请号：EP14184761.6

申请日：2012-12-11

申请人： Oncostamen S.r.l.

发明人： De Maria Marchiano, Ruggero ,  Coppola, Valeria ,  Todaro, Matilde ,  Fiori, Micol Eleonora ,  Garaci, Enrico

IPC分类号： C12N15/113 ,  A61K31/7105 ,  A61K31/712 ,  A61P35/00

CPC分类号： C12N15/1135 ,  A61K31/337 ,  A61K31/7105 ,  A61K31/712 ,  A61K33/24 ,  C12N2310/113 ,  C12N2310/141 ,  C12N2310/3231

摘要： The invention relates to pharmaceutical compositions comprising an antagonist of hsa-miR-361-3p or hsa-miR-1285 and their use to counteract tumors, in particular of the breast or lung. Said compositions may further contain a chemotherapeutic drug.

公开(公告)号：EP2707486A4

公开(公告)日：2015-02-18

申请号：EP12767650

申请日：2012-04-04

申请人： ZAIN LUQMAN RULA

发明人： BERGQUIST HELEN ,  GOOD LIAM

IPC分类号： C12Q1/68 ,  A61K31/712 ,  C12N15/113

CPC分类号： C12N15/113 ,  A61K31/712 ,  C12N2310/11 ,  C12N2310/3181 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2320/30 ,  C12Q1/6883 ,  C12Q2600/156

摘要： The present invention is directed to oligonucleotides based on peptide nucleic acid oligonucleotide or an equivalent oligonucleotide analogue, such as morpholino or a locked nucleic acid sequences and the use of such oligonucleotides for the dissociation of higher order structures, including triplex-helix DNA structures, in repeated sequences of DNA in Friedreich's ataxia. The dissociation of such structures may be used in the diagnosis and/or treatment of Friedreich's ataxia. Consequently, the present invention is also directed to a method for diagnosing Friedreich's ataxia and the use of peptide nucleic acid oligonucleotide or an equivalent oligonucleotide analogue, such as morpholino or a locked nucleic acid sequences in the treatment of Friedreich's ataxia. Preferably, the oligonucleotides comprise a sequence selected from the group consisting of (GAA)n, (CTT)n, (JTT)n or a mixed (JTT/CTT)n sequence.

公开(公告)号：EP2685990A4

公开(公告)日：2014-09-17

申请号：EP12757133

申请日：2012-03-12

申请人： UNIV BRITISH COLUMBIA

发明人： GLEAVE MARTIN E ,  ZOUBEIDI AMINA ,  LAMOUREUX FRANÇOIS

IPC分类号： A61K31/7088 ,  A61K31/4162 ,  A61P35/00

CPC分类号： C12N15/1135 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/7088 ,  A61K31/712 ,  A61K31/713 ,  A61K45/06 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2320/31 ,  A61K2300/00

公开(公告)号：EP2535410A4

公开(公告)日：2014-08-13

申请号：EP11742319

申请日：2011-02-10

申请人： RIBOMIC INC

发明人： NAKAMURA YOSHIKAZU ,  ISHIGURO AKIRA ,  SAKAMOTO MAIKO

IPC分类号： C12N15/09 ,  A61K31/712 ,  A61P9/00 ,  A61P19/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06 ,  A61P37/08 ,  C12N15/115 ,  C12Q1/68

CPC分类号： C12N15/115 ,  A61K31/7105 ,  A61K31/712 ,  C12N2310/16 ,  C12N2310/322 ,  C12N2310/344

公开(公告)号：EP1507791B1

公开(公告)日：2013-12-18

申请号：EP02776222.8

申请日：2002-10-16

申请人： Sarepta Therapeutics, Inc.

发明人： STEIN, David, A. ,  SKILLING, Douglas, E. ,  IVERSEN, Patrick, L. ,  SMITH, Alvin, W.

IPC分类号： C12N15/113 ,  C07H21/04 ,  A61K31/712

CPC分类号： A61K31/712 ,  A61K31/7125 ,  A61K38/00 ,  C12N15/1131 ,  C12N2310/3145 ,  C12N2310/3233 ,  Y02A50/463

摘要： The invention provides antisense antiviral compounds and methods of their use in inhibition of growth of viruses of the picornavirus, calicivirus, togavirus and flavivirus families, as in treatment of a viral infection. The antisense antiviral compounds are substantially uncharged oligomers having a targeting base sequence that is substantially complementary to a viral target sequence which spans the AUG start site of the first open reading frame of the viral genome.

公开(公告)号：EP2440183A4

公开(公告)日：2013-02-27

申请号：EP10786869

申请日：2010-06-10

申请人： ALNYLAM PHARMACEUTICALS INC

发明人： AKINC AKIN ,  DORKIN JOSEPH R ,  QIN XIAOJUN ,  CANTLEY WILLIAM ,  MANOHARAN MUTHIAH ,  RAJEEV KALLANTHOTTATHIL G ,  NARAYANANNAIR JAYAPRAKASH K ,  JAYARAMAN MUTHUSAMY ,  CHEN JIANXIN ,  ANSELL STEVEN

IPC分类号： A61K9/127 ,  A61K31/20 ,  A61K47/48 ,  A61K48/00 ,  C07C211/00 ,  C12N5/00

CPC分类号： A61K9/1272 ,  A61K9/1278 ,  A61K31/22 ,  A61K31/7088 ,  A61K31/712 ,  A61K31/713 ,  A61K38/1709 ,  A61K38/4846 ,  A61K47/14 ,  A61K47/48092 ,  A61K47/48107 ,  A61K47/48815 ,  A61K47/549 ,  A61K47/551 ,  A61K47/6911 ,  A61K48/0033 ,  C07C29/58 ,  C07C227/18 ,  C07C227/40 ,  C07C229/12 ,  C07D475/04 ,  C12N15/113 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/351 ,  C12N2310/3515 ,  C12N2320/32 ,  A61K2300/00 ,  C12N2310/3521 ,  C12N2310/3533

摘要： The invention features a cationic lipid of formula I, an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.

摘要翻译： 本发明的特征在于式I的阳离子脂质，包含式I的阳离子脂质和相应的使用方法的改进的脂质制剂。 还公开了靶向脂质和包含这种靶向脂质的特定脂质制剂。

公开(公告)号：EP2319519A4

公开(公告)日：2013-01-09

申请号：EP09803053

申请日：2009-07-31

申请人： KYOWA HAKKO KIRIN CO LTD

发明人： YAGI NOBUHIRO ,  ENOKIZONO JUNICHI

IPC分类号： A61K31/712 ,  A61K9/127 ,  A61K31/7105 ,  A61K31/713 ,  A61K47/10 ,  A61K47/18 ,  A61K47/24 ,  A61K47/28 ,  A61K47/34 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C12N15/113

CPC分类号： A61K31/7105 ,  A61K9/0019 ,  A61K9/1271 ,  A61K31/712 ,  A61K31/713 ,  C12N15/1135 ,  C12N2310/14 ,  Y10T436/143333

公开(公告)号：EP2314693A3

公开(公告)日：2012-11-28

申请号：EP10010051.0

申请日：2000-08-14

申请人： Idera Pharmaceuticals, Inc.

发明人： Agrawal, Sudhir

IPC分类号： C12N15/117 ,  A61K31/7125 ,  C07H21/00

CPC分类号： A61K31/7115 ,  A61K31/711 ,  A61K31/712 ,  A61K31/7125 ,  A61K2039/55561 ,  C12N15/117 ,  C12N2310/18 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/346 ,  C12N2310/3521 ,  C12N2310/3125

摘要： The invention provides methods for modulating the immune response caused by CpG-containing oligonucleotides. The methods according to the invention enable decreasing the immunostimulatory effect for antisense applications.

公开(公告)号：EP2440215A1

公开(公告)日：2012-04-18

申请号：EP10724511.0

申请日：2010-06-14

申请人： Santaris Pharma A/S

发明人： NIELSEN, Niels Fisker ,  STRAARUP, Ellen Marie ,  LINDHOLM, Marie

IPC分类号： A61K31/712 ,  A61K31/713 ,  C12N15/113 ,  A61P9/10

CPC分类号： C12N15/113 ,  A61K31/712 ,  A61K31/713 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/3521 ,  C12N2310/3533

摘要： The present invention relates to oligomer compounds (oligomers), which target APO- B100 mRNA in a cell, leading to reduced expression of APO-B100. Reduction of APO-B100 expression is beneficial for the treatment of certain medical disorders, such as diseases associated with apolipoproteinB activity, such as in non-limiting example, different types of HDL/LDL cholesterol imbalance; dyslipidemias, e.g., familial combined hyperlipidemia (FCHL), acquired hyperlipidemia, hypercholesterolemia, statin-resistant hypercholesterolemia; coronary artery disease (CAD), coronary heart disease (CHD), atherosclerosis.

公开(公告)号：EP2411018A2

公开(公告)日：2012-02-01

申请号：EP10710764.1

申请日：2010-03-25

申请人： Merck Sharp&Dohme Corp.

发明人： STRAPPS, Walter ,  JADHAV, Vasant ,  PICKERING, Victoria

IPC分类号： A61K31/712 ,  A61K31/713 ,  C12N15/113 ,  A61P11/00

CPC分类号： C12N15/1136 ,  A61K31/712 ,  A61K31/713 ,  C12N2310/14 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3521 ,  C12N2310/3533

摘要： The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of NGFβ gene expression and/or activity, and/or modulate a NGFβ gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against NGFβ gene expression.